BG108368A - Използване на инхибитори на hiv-протеаза за блокиране на клетъчна миграция и/или инвазия, инфилтрация на тъкан и формация на оток - Google Patents
Използване на инхибитори на hiv-протеаза за блокиране на клетъчна миграция и/или инвазия, инфилтрация на тъкан и формация на оток Download PDFInfo
- Publication number
- BG108368A BG108368A BG108368A BG10836803A BG108368A BG 108368 A BG108368 A BG 108368A BG 108368 A BG108368 A BG 108368A BG 10836803 A BG10836803 A BG 10836803A BG 108368 A BG108368 A BG 108368A
- Authority
- BG
- Bulgaria
- Prior art keywords
- hiv
- blocking
- inflammatory
- cells
- saquinavir
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 38
- 206010030113 Oedema Diseases 0.000 title claims abstract description 34
- 239000004030 hiv protease inhibitor Substances 0.000 title claims description 142
- 230000004709 cell invasion Effects 0.000 title claims description 62
- 230000012292 cell migration Effects 0.000 title claims description 28
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 79
- 210000001519 tissue Anatomy 0.000 claims abstract description 60
- 230000009545 invasion Effects 0.000 claims abstract description 59
- 238000000034 method Methods 0.000 claims abstract description 57
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 51
- 230000008595 infiltration Effects 0.000 claims abstract description 45
- 238000001764 infiltration Methods 0.000 claims abstract description 45
- 108091005804 Peptidases Proteins 0.000 claims abstract description 40
- 102000035195 Peptidases Human genes 0.000 claims abstract description 39
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims abstract description 33
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims abstract description 33
- 230000001613 neoplastic effect Effects 0.000 claims abstract description 28
- 210000004969 inflammatory cell Anatomy 0.000 claims abstract description 26
- 201000010099 disease Diseases 0.000 claims abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 24
- 210000002865 immune cell Anatomy 0.000 claims abstract description 24
- 239000004365 Protease Substances 0.000 claims abstract description 23
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 19
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 claims abstract description 17
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 16
- 239000003112 inhibitor Substances 0.000 claims abstract 2
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims description 252
- 210000004027 cell Anatomy 0.000 claims description 249
- 229960001852 saquinavir Drugs 0.000 claims description 249
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims description 245
- 229960001936 indinavir Drugs 0.000 claims description 242
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 151
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 151
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 149
- 230000000694 effects Effects 0.000 claims description 122
- 230000000903 blocking effect Effects 0.000 claims description 74
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims description 59
- 230000033115 angiogenesis Effects 0.000 claims description 56
- 238000011282 treatment Methods 0.000 claims description 54
- 101710151806 72 kDa type IV collagenase Proteins 0.000 claims description 53
- 210000002889 endothelial cell Anatomy 0.000 claims description 53
- 230000005012 migration Effects 0.000 claims description 42
- 238000013508 migration Methods 0.000 claims description 42
- 230000001772 anti-angiogenic effect Effects 0.000 claims description 35
- 230000001225 therapeutic effect Effects 0.000 claims description 35
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 33
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 33
- 102000004127 Cytokines Human genes 0.000 claims description 32
- 108090000695 Cytokines Proteins 0.000 claims description 32
- 230000000259 anti-tumor effect Effects 0.000 claims description 30
- 238000004519 manufacturing process Methods 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 28
- 230000001413 cellular effect Effects 0.000 claims description 25
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 22
- 101710149951 Protein Tat Proteins 0.000 claims description 21
- 230000002401 inhibitory effect Effects 0.000 claims description 21
- 210000004881 tumor cell Anatomy 0.000 claims description 21
- 230000008728 vascular permeability Effects 0.000 claims description 21
- 230000004614 tumor growth Effects 0.000 claims description 15
- 102000002938 Thrombospondin Human genes 0.000 claims description 14
- 108060008245 Thrombospondin Proteins 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 230000003511 endothelial effect Effects 0.000 claims description 12
- 229940088598 enzyme Drugs 0.000 claims description 12
- 230000003501 anti-edematous effect Effects 0.000 claims description 11
- 230000002792 vascular Effects 0.000 claims description 11
- 108090000855 Matrilysin Proteins 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 210000005170 neoplastic cell Anatomy 0.000 claims description 10
- 108091007196 stromelysin Proteins 0.000 claims description 10
- 206010061218 Inflammation Diseases 0.000 claims description 9
- 230000004054 inflammatory process Effects 0.000 claims description 9
- 230000001575 pathological effect Effects 0.000 claims description 9
- 201000004681 Psoriasis Diseases 0.000 claims description 8
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 206010027476 Metastases Diseases 0.000 claims description 7
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 7
- 230000003213 activating effect Effects 0.000 claims description 7
- 229960001830 amprenavir Drugs 0.000 claims description 7
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 claims description 7
- 229960000311 ritonavir Drugs 0.000 claims description 7
- 241000700605 Viruses Species 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 229940041181 antineoplastic drug Drugs 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 230000009401 metastasis Effects 0.000 claims description 6
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims description 6
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims description 5
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 5
- 230000001771 impaired effect Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 229960000884 nelfinavir Drugs 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- OFFWOVJBSQMVPI-RMLGOCCBSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O.N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 OFFWOVJBSQMVPI-RMLGOCCBSA-N 0.000 claims description 4
- 208000002260 Keloid Diseases 0.000 claims description 4
- 206010039710 Scleroderma Diseases 0.000 claims description 4
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 4
- 208000004732 Systemic Vasculitis Diseases 0.000 claims description 4
- 208000025865 Ulcer Diseases 0.000 claims description 4
- 206010047115 Vasculitis Diseases 0.000 claims description 4
- 208000026935 allergic disease Diseases 0.000 claims description 4
- 230000007815 allergy Effects 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 230000031018 biological processes and functions Effects 0.000 claims description 4
- 210000000988 bone and bone Anatomy 0.000 claims description 4
- 210000000845 cartilage Anatomy 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 201000001371 inclusion conjunctivitis Diseases 0.000 claims description 4
- 230000002458 infectious effect Effects 0.000 claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 4
- 210000001117 keloid Anatomy 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 229940120922 lopinavir and ritonavir Drugs 0.000 claims description 4
- 230000003071 parasitic effect Effects 0.000 claims description 4
- 230000007170 pathology Effects 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 210000004872 soft tissue Anatomy 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 206010043778 thyroiditis Diseases 0.000 claims description 4
- 206010044325 trachoma Diseases 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 206010036774 Proctitis Diseases 0.000 claims description 3
- 230000001363 autoimmune Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 229940122440 HIV protease inhibitor Drugs 0.000 claims 5
- 102000004318 Matrilysin Human genes 0.000 claims 5
- 230000004640 cellular pathway Effects 0.000 claims 4
- 238000007912 intraperitoneal administration Methods 0.000 claims 4
- 238000007913 intrathecal administration Methods 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 3
- 238000007920 subcutaneous administration Methods 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 206010004659 Biliary cirrhosis Diseases 0.000 claims 1
- 208000005024 Castleman disease Diseases 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract description 31
- 230000005764 inhibitory process Effects 0.000 abstract description 18
- 230000008569 process Effects 0.000 abstract description 11
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- -1 but not exclusively Proteins 0.000 abstract description 3
- 230000008506 pathogenesis Effects 0.000 abstract description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 230000003902 lesion Effects 0.000 description 81
- 239000000872 buffer Substances 0.000 description 76
- 238000011081 inoculation Methods 0.000 description 67
- 241000699670 Mus sp. Species 0.000 description 62
- 241000699660 Mus musculus Species 0.000 description 55
- 238000011580 nude mouse model Methods 0.000 description 55
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 45
- 230000006378 damage Effects 0.000 description 41
- 238000002347 injection Methods 0.000 description 37
- 239000007924 injection Substances 0.000 description 37
- 239000011780 sodium chloride Substances 0.000 description 32
- 238000010586 diagram Methods 0.000 description 31
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 29
- 241001465754 Metazoa Species 0.000 description 28
- 239000013024 dilution buffer Substances 0.000 description 28
- 108010082117 matrigel Proteins 0.000 description 28
- 230000004044 response Effects 0.000 description 27
- 238000011161 development Methods 0.000 description 26
- 230000018109 developmental process Effects 0.000 description 26
- 230000035755 proliferation Effects 0.000 description 25
- 230000012010 growth Effects 0.000 description 24
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 21
- 230000002491 angiogenic effect Effects 0.000 description 20
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 19
- 239000006228 supernatant Substances 0.000 description 17
- 102000004889 Interleukin-6 Human genes 0.000 description 16
- 108090001005 Interleukin-6 Proteins 0.000 description 16
- 238000001727 in vivo Methods 0.000 description 16
- 238000000338 in vitro Methods 0.000 description 15
- 238000010186 staining Methods 0.000 description 15
- 206010006187 Breast cancer Diseases 0.000 description 14
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 14
- 230000004663 cell proliferation Effects 0.000 description 14
- 239000005018 casein Substances 0.000 description 13
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 13
- 235000021240 caseins Nutrition 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 230000004913 activation Effects 0.000 description 12
- 201000005202 lung cancer Diseases 0.000 description 12
- 208000020816 lung neoplasm Diseases 0.000 description 12
- 210000004379 membrane Anatomy 0.000 description 12
- 208000026310 Breast neoplasm Diseases 0.000 description 11
- 230000000477 gelanolytic effect Effects 0.000 description 11
- 238000011534 incubation Methods 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 10
- 206010024305 Leukaemia monocytic Diseases 0.000 description 9
- 239000002975 chemoattractant Substances 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 201000006894 monocytic leukemia Diseases 0.000 description 9
- 239000012679 serum free medium Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 8
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 8
- 239000002870 angiogenesis inducing agent Substances 0.000 description 8
- 230000034994 death Effects 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 108010010803 Gelatin Proteins 0.000 description 7
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000008273 gelatin Substances 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 235000011852 gelatine desserts Nutrition 0.000 description 7
- 201000005296 lung carcinoma Diseases 0.000 description 7
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 7
- 210000003606 umbilical vein Anatomy 0.000 description 7
- 208000030507 AIDS Diseases 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 6
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 6
- 206010025323 Lymphomas Diseases 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 6
- 208000019420 lymphoid neoplasm Diseases 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 6
- 239000004417 polycarbonate Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 239000013545 self-assembled monolayer Substances 0.000 description 6
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 102000000589 Interleukin-1 Human genes 0.000 description 5
- 108010002352 Interleukin-1 Proteins 0.000 description 5
- 102100030417 Matrilysin Human genes 0.000 description 5
- 229930012538 Paclitaxel Natural products 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 229960001592 paclitaxel Drugs 0.000 description 5
- 229920000515 polycarbonate Polymers 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 150000004992 toluidines Chemical class 0.000 description 5
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 108010010369 HIV Protease Proteins 0.000 description 4
- 102000005741 Metalloproteases Human genes 0.000 description 4
- 108010006035 Metalloproteases Proteins 0.000 description 4
- 230000000468 autoproteolytic effect Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 210000004754 hybrid cell Anatomy 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 3
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 3
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 3
- 208000000389 T-cell leukemia Diseases 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003305 autocrine Effects 0.000 description 3
- 201000008274 breast adenocarcinoma Diseases 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 235000003642 hunger Nutrition 0.000 description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 208000015325 multicentric Castleman disease Diseases 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000003076 paracrine Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000037351 starvation Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 2
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010055166 Chemokine CCL5 Proteins 0.000 description 2
- 102100026735 Coagulation factor VIII Human genes 0.000 description 2
- 102000010911 Enzyme Precursors Human genes 0.000 description 2
- 108010062466 Enzyme Precursors Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000798 anti-retroviral effect Effects 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 230000009702 cancer cell proliferation Effects 0.000 description 2
- 230000009400 cancer invasion Effects 0.000 description 2
- 230000000963 caseinolytic effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000009087 cell motility Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000002900 effect on cell Effects 0.000 description 2
- 230000010595 endothelial cell migration Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 229960003699 evans blue Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000002390 hyperplastic effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 229960004525 lopinavir Drugs 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 239000002644 phorbol ester Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000216 vascular lesion Toxicity 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical compound OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 101100072305 Mus musculus Ift57 gene Proteins 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 102000004140 Oncostatin M Human genes 0.000 description 1
- 108090000630 Oncostatin M Proteins 0.000 description 1
- 241000283283 Orcinus orca Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 102100028848 Stromelysin-2 Human genes 0.000 description 1
- 101710108792 Stromelysin-2 Proteins 0.000 description 1
- 102100028847 Stromelysin-3 Human genes 0.000 description 1
- 108050005271 Stromelysin-3 Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- LUTSRLYCMSCGCS-BWOMAWGNSA-N [(3s,8r,9s,10r,13s)-10,13-dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,16-decahydrocyclopenta[a]phenanthren-3-yl] acetate Chemical compound C([C@@H]12)C[C@]3(C)C(=O)CC=C3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)C)C1 LUTSRLYCMSCGCS-BWOMAWGNSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001601 blood-air barrier Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000002701 cell growth assay Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229940088900 crixivan Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 239000002852 cysteine proteinase inhibitor Substances 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 231100000767 hemotoxin Toxicity 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 230000007768 histopathological growth pattern Effects 0.000 description 1
- 230000000652 homosexual effect Effects 0.000 description 1
- 102000043827 human Smooth muscle Human genes 0.000 description 1
- 108700038605 human Smooth muscle Proteins 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229940088976 invirase Drugs 0.000 description 1
- 229940112586 kaletra Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007762 localization of cell Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 229940072250 norvir Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001373 regressive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000682 scanning probe acoustic microscopy Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007801 sublethal irradiation Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 231100000155 toxicity by organ Toxicity 0.000 description 1
- 230000007675 toxicity by organ Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 206010055031 vascular neoplasm Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940023080 viracept Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001RM000210A ITRM20010210A1 (it) | 2001-04-18 | 2001-04-18 | Uso degli inibitori della proteasi del virus dell'immunodeficienza umana (hiv)nella terapia del sarcoma di kaposi, dei tumori e delle malatt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG108368A true BG108368A (bg) | 2005-01-31 |
Family
ID=11455472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG108368A BG108368A (bg) | 2001-04-18 | 2003-11-18 | Използване на инхибитори на hiv-протеаза за блокиране на клетъчна миграция и/или инвазия, инфилтрация на тъкан и формация на оток |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20060088545A1 (fr) |
| EP (1) | EP1401447A2 (fr) |
| CN (1) | CN1700916A (fr) |
| AP (1) | AP2003002901A0 (fr) |
| BG (1) | BG108368A (fr) |
| CA (1) | CA2447748A1 (fr) |
| CZ (1) | CZ20033113A3 (fr) |
| EA (1) | EA006678B1 (fr) |
| EE (1) | EE200300507A (fr) |
| HU (1) | HUP0401199A2 (fr) |
| IT (1) | ITRM20010210A1 (fr) |
| MX (1) | MXPA03010380A (fr) |
| SK (1) | SK14212003A3 (fr) |
| WO (1) | WO2002087583A2 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002346594A1 (en) * | 2001-12-14 | 2003-06-30 | Cedars-Sinai Medical Center | Use of hiv-1 protease inhibitors and their derivatives in the treatment of inflammation |
| US7812034B2 (en) * | 2003-11-04 | 2010-10-12 | City Of Hope | Method of using protease inhibitors for the treatment of liposarcomas |
| US20090010990A1 (en) * | 2007-06-20 | 2009-01-08 | Little Marisa A | Process for depositing calcium phosphate therapeutic coatings with controlled release rates and a prosthesis coated via the process |
| WO2011139378A1 (fr) * | 2010-05-06 | 2011-11-10 | The Feinstein Institute For Medical Research | Composés et méthodes de traitement du lupus érythémateux systémique |
| EP2654791A4 (fr) * | 2010-12-22 | 2014-07-09 | The Feinstein Inst Medical Res | Procédés pour traiter le lupus érythémateux disséminé utilisant des inhibiteurs de protéase du vih |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2779653B1 (fr) * | 1998-06-11 | 2002-12-20 | Inst Nat Sante Rech Med | Utilisation de composes modulateurs du proteasome en therapie |
| WO2000033654A1 (fr) * | 1998-12-04 | 2000-06-15 | University Of Maryland Biotechnology Institute | Utilisation d'inhibiteurs de protease pour moduler les chemins cellulaires, immunite et therapies associees |
-
2001
- 2001-04-18 IT IT2001RM000210A patent/ITRM20010210A1/it unknown
-
2002
- 2002-04-18 SK SK1421-2003A patent/SK14212003A3/sk unknown
- 2002-04-18 MX MXPA03010380A patent/MXPA03010380A/es not_active Application Discontinuation
- 2002-04-18 AP APAP/P/2003/002901A patent/AP2003002901A0/en unknown
- 2002-04-18 CZ CZ20033113A patent/CZ20033113A3/cs unknown
- 2002-04-18 WO PCT/EP2002/004303 patent/WO2002087583A2/fr not_active Application Discontinuation
- 2002-04-18 EE EEP200300507A patent/EE200300507A/xx unknown
- 2002-04-18 US US10/549,958 patent/US20060088545A1/en not_active Abandoned
- 2002-04-18 EA EA200301130A patent/EA006678B1/ru not_active IP Right Cessation
- 2002-04-18 CA CA002447748A patent/CA2447748A1/fr not_active Abandoned
- 2002-04-18 EP EP02766632A patent/EP1401447A2/fr not_active Ceased
- 2002-04-18 HU HU0401199A patent/HUP0401199A2/hu unknown
- 2002-04-18 CN CNA028121260A patent/CN1700916A/zh active Pending
-
2003
- 2003-11-18 BG BG108368A patent/BG108368A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ITRM20010210A0 (it) | 2001-04-18 |
| MXPA03010380A (es) | 2004-03-16 |
| EP1401447A2 (fr) | 2004-03-31 |
| CZ20033113A3 (cs) | 2004-07-14 |
| US20060088545A1 (en) | 2006-04-27 |
| EE200300507A (et) | 2004-02-16 |
| CN1700916A (zh) | 2005-11-23 |
| CA2447748A1 (fr) | 2002-11-07 |
| HUP0401199A2 (hu) | 2004-12-28 |
| EA200301130A1 (ru) | 2004-04-29 |
| WO2002087583A2 (fr) | 2002-11-07 |
| EA006678B1 (ru) | 2006-02-24 |
| ITRM20010210A1 (it) | 2002-10-18 |
| SK14212003A3 (sk) | 2004-06-08 |
| AP2003002901A0 (en) | 2003-12-31 |
| WO2002087583A3 (fr) | 2002-12-19 |
| WO2002087583B1 (fr) | 2003-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fatahzadeh | Kaposi sarcoma: review and medical management update | |
| Cruz et al. | Leishmania/HIV co-infections in the second decade | |
| RU2724339C2 (ru) | Сенекривирок для лечения фиброза | |
| Groschwitz et al. | Chymase-mediated intestinal epithelial permeability is regulated by a protease-activating receptor/matrix metalloproteinase-2-dependent mechanism | |
| JP2020196750A (ja) | 線維症を処置するためのセニクリビロック併用療法 | |
| Toschi et al. | Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via a proteasome‐independent block of angiogenesis and matrix metalloproteinases | |
| Escribano et al. | Current options in the treatment of mast cell mediator-related symptoms in mastocytosis | |
| JP5232678B2 (ja) | 新形成細胞の細胞消滅死を誘導する方法 | |
| AU2019210999B2 (en) | Use of minaprine to reduce tumor growth | |
| Rosanò et al. | Endothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth in vivo | |
| Yoon et al. | Gabexate mesilate inhibits colon cancer growth, invasion, and metastasis by reducing matrix metalloproteinases and angiogenesis | |
| Xie et al. | Panax quinquefolium saponin inhibits endoplasmic reticulum stress-induced apoptosis and the associated inflammatory response in chondrocytes and attenuates the progression of osteoarthritis in rat | |
| BG108368A (bg) | Използване на инхибитори на hiv-протеаза за блокиране на клетъчна миграция и/или инвазия, инфилтрация на тъкан и формация на оток | |
| JP7229565B2 (ja) | メラノーマを治療するための方法 | |
| AU2002338495A1 (en) | Use of HIV-protease inhibitors to block cell migration and/or invasion, tissue infiltration and oedema formation | |
| CN115427077A (zh) | 肝衰竭的治疗 | |
| KR20210056931A (ko) | 피리메타민을 유효성분으로 포함하는 면역 관련 질환의 치료 또는 예방용 약학 조성물 | |
| Chen et al. | Galloyl cyclic-imide derivative CH1104I inhibits tumor invasion through suppressing matrix metalloproteinase activity | |
| KR101976633B1 (ko) | 폐 섬유증의 예방 또는 치료용 약학적 조성물 | |
| KR102115557B1 (ko) | 폐 섬유증의 예방 또는 치료용 약학적 조성물 | |
| RU2816314C1 (ru) | Виды комбинированной терапии для лечения рака | |
| KR101988124B1 (ko) | 암 연관 섬유아세포 표적용 약학적 조성물 | |
| CN101507720A (zh) | 调节血管生成和癌细胞增殖的方法 | |
| Miles | Cytokines, Viruses, Angiogenesis | |
| Ratih et al. | Senescence-Induced Atherosclerosis: The Potency of Senolytic Therapy |